Recombinant IL6 Canine Protein [E. Coli.] (MAG-1706)

IL6 Canine Protein

MAG-1706

His

Sf9, Baculovirus cells.

Shipped with Ice Packs

IL6 Canine Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 195 amino acids (21-207a.a.) and having a molecular mass of 22.0kDa (Molecular size on SDS-PAGE will appear at approximately 18-28kDa). IL6 is expressed with an 8 amino acid His-tag at C-Terminus and purified by proprietary chromatographic techniques.

IL6, IL-6, Interleukin-6.

Il-6 is a cytokine with a wide variety of biological functions: it plays an essential role in the final differentiation of b-cells into ig-secreting cells, it induces myeloma and plasmacytoma growth, it induces nerve cells differentiation, in hepatocytes it induces acute phase reactants.

/

Sterile Filtered colorless solution.

IL6 protein solution (0.5mg/ml) contains Phosphate Buffered Saline (pH 7.4) and 10% glycerol.

/

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

Greater than 95.0% as determined by SDS-PAGE.

FPTPGPLAGD SKDDATSNSL PLTSANKVEE LIKYILGKIS ALRKEMCDKF NKCEDSKEAL AENNLHLPKL EGKDGCFQSG FNQETCLTRI TTGLVEFQLH LNILQNNYEG DKENVKSVHM STKILVQMLK SKVKNQDEVT TPDPTTDASL QAILQSQDEC VKHTTIHLIL RSLEDFLQFS LRAVRIM LEH HHHHH .

Mabioway's Co., Ltd products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Canine IL-6 Recombinant: Implications for Immunotherapy and Veterinary Medicine Abstract: Interleukin-6 (IL-6) plays a pivotal role in the immune response and inflammation regulation in various species, including canines. The advent of recombinant DNA technology has enabled the production of Canine IL-6 Recombinant (cIL-6r), opening new avenues for research in immunotherapy and veterinary medicine. This paper delves into the significance of cIL-6r, its production methods, and its potential applications in the treatment of inflammatory and autoimmune diseases in dogs. Introduction: Interleukin-6 is a multifunctional cytokine that exerts its effects on a wide range of physiological processes, including immune responses, hematopoiesis, and inflammation. In the canine immune system, IL-6 plays a crucial role in coordinating immune cell activation, antibody production, and acute phase responses. Recombinant IL-6 production has emerged as a promising strategy to harness its therapeutic potential. Methods: The production of cIL-6r involves recombinant DNA technology, where the canine IL-6 gene is inserted into an expression vector and transfected into a suitable host cell line, typically bacterial or mammalian cells. The recombinant protein is then purified using various chromatographic techniques to ensure high purity and biological activity. Applications: Canine IL-6 Recombinant holds immense promise in various applications within veterinary medicine. Its immunomodulatory properties make it a potential candidate for treating conditions such as immune-mediated diseases, inflammatory disorders, and certain types of cancer in dogs. Additionally, cIL-6r can be utilized to stimulate immune responses in vaccines, thereby enhancing their efficacy. Challenges and Future Directions: While cIL-6r shows great potential, its therapeutic use requires comprehensive studies to establish optimal dosages, safety profiles, and potential side effects. Long-term effects and potential interactions with existing treatments must also be explored. Conclusion: The advent of Canine IL-6 Recombinant marks a significant advancement in veterinary medicine, offering new avenues for immunotherapy and disease management in dogs. With further research and development, cIL-6r could become an invaluable tool in treating various conditions, ultimately enhancing the health and well-being of our canine companions.